We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+6.12%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$1.93B
AUM Growth
-$220M
(-10%)
Cap. Flow
-$774M
Cap. Flow
% of AUM
-40.09%
Top 10 Holdings %
Top 10 Hldgs %
34.72%
Holding
143
New
28
Increased
19
Reduced
29
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$75.2M |
| 2 |
Humana
HUM
|
+$40.6M |
| 3 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
+$30.6M |
| 4 |
DaVita
DVA
|
+$28.5M |
| 5 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
+$25.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$51.8M |
| 2 |
AstraZeneca
AZN
|
+$48.2M |
| 3 |
AbbVie
ABBV
|
+$45M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$35M |
| 5 |
THOR
THORATEC CORPORATION
THOR
|
+$33.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.08% |
| 2 | Financials | 1.16% |
| 3 | Technology | 0.74% |
| 4 | Industrials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AUXL
1
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $85.3M | 4.42% |
4,113,385
+1,625,057
| +65% | +$30.6M |
|
|
QCOR
2
DELISTED
QUESTCOR PHARMA INC
QCOR
| $82M | 4.25% |
1,506,297
+1,272,530
| +544% | +$75.2M |
|
|
CBST
3
CALL
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $68.9M | 3.57% |
1,000,000
-500,000
| -33% | -$32.4M |
|
|
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
| $56.3M | 2.92% |
11,235,406
+650,000
| +6% | +$3.54M |
|
|
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
| $55.7M | 2.89% |
5,570,639
+543,475
| +11% | +$6.17M |
|
|
INFI
6
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $55M | 2.85% |
3,981,743
+1,809,999
| +83% | +$25.6M |
|
|
ATRS
7
DELISTED
Antares Pharma, Inc.
ATRS
| $45.3M | 2.35% |
10,141,174
+1,488,055
| +17% | +$6.06M |
|
|
8
Humana
HUM
$48B
| $42.8M | 2.22% |
+414,670
| New | +$40.6M |
|
9
Merck
MRK
$315B
| $36.3M | 1.88% |
759,800
+262,000
| +53% | +$12M |
|
|
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $35.3M | 1.83% |
+4,638,888
| New | +$25M |
|
|
AVDL
11
DELISTED
Avadel Pharmaceuticals
AVDL
| $34.9M | 1.81% |
4,333,475
| – | – |
|
12
Globus Medical
GMED
$10.5B
| $34.2M | 1.77% |
1,694,472
+496,707
| +41% | +$9.22M |
|
13
Sonida Senior Living
SNDA
$1.93B
| $34M | 1.76% |
94,541
+24,498
| +35% | +$8.16M |
|
|
UAM
14
DELISTED
Universal American Corp
UAM
| $33.6M | 1.74% |
4,600,692
+1,674,592
| +57% | +$12.5M |
|
|
15
DaVita
DVA
$15.2B
| $30.7M | 1.59% |
+485,000
| New | +$28.5M |
|
|
16
CALL
Humana
HUM
$48B
| $28.9M | 1.5% |
+280,000
| New | +$27.4M |
|
|
TRNX
17
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $28.4M | 1.47% |
1,509,974
+51,903
| +4% | +$978K |
|
|
QCOR
18
CALL
DELISTED
QUESTCOR PHARMA INC
QCOR
| $27.2M | 1.41% |
+500,000
| New | +$29.6M |
|
|
CBST
19
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $26.6M | 1.38% |
386,282
-167,718
| -30% | -$10.9M |
|
|
XOMA
20
DELISTED
Xoma
XOMA
| $25.6M | 1.33% |
190,343
-114,489
| -38% | -$11.5M |
|
|
DYAX
21
DELISTED
DYAX CORPORATION
DYAX
| $25.3M | 1.31% |
3,357,747
-1,074,878
| -24% | -$8.16M |
|
22
Pacific Biosciences
PACB
$447M
| $22.8M | 1.18% |
4,351,262
-533,106
| -11% | -$2.45M |
|
|
AET
23
DELISTED
Aetna Inc
AET
| $22.4M | 1.16% |
327,000
-26,000
| -7% | -$1.7M |
|
24
Molina Healthcare
MOH
$11.7B
| $22.4M | 1.16% |
644,971
+185,971
| +41% | +$6.27M |
|
|
XNPT
25
DELISTED
XENOPORT, INC.
XNPT
| $21.4M | 1.11% |
3,719,040
-886,936
| -19% | -$4.8M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q4 2013 Portfolio in Review
As of Q4 2013, Deerfield Management held 143 positions worth $1.93B, down 10% from $2.15B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Deerfield Management withdrew a net $774M in Q4 2013, closing 37 positions and reducing 29 holdings. Its most notable exit was Pfizer, an estimated $51.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 52% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in Humana worth $42.8M.
- Deerfield Management's largest Q4 2013 buy was Humana: 414,670 shares worth $42.8M.
- Deerfield Management added most to QUESTCOR PHARMA INC in Q4 2013, an estimated $75.2M increase.
- Deerfield Management's biggest Q4 2013 reduction was Teva Pharmaceuticals, cutting an estimated $35M.
- Deerfield Management fully exited Pfizer in Q4 2013, selling an estimated $51.8M.
- Deerfield Management's ten largest holdings make up 35% of its $1.93B portfolio in Q4 2013.
- Deerfield Management opened 28 new positions and closed 37 in Q4 2013.
- Deerfield Management's portfolio value fell 10% quarter-over-quarter to $1.93B.
Based on Deerfield Management's 13F filing for Q4 2013, filed 14 Feb 2014.